

<ul style="list-style-type: none"><li>• Electronic copy is controlled under document control procedure. Hard copy is uncontrolled &amp; under responsibility of beholder.</li><li>• It is allowed ONLY to access and keep this document with who issued, who is responsible and to whom it is applicable.</li><li>• Information security code: <input checked="" type="checkbox"/> Open <input type="checkbox"/> Shared -Confidential <input type="checkbox"/> Shared-Sensitive <input type="checkbox"/> Shared-Secret</li></ul>	<ul style="list-style-type: none"><li>• النسخة الإلكترونية هي النسخة المضبوطة وفق إجراء ضبط الوثائق- النسخ الورقية غير مضبوطة وتقع على مسؤولية حاملها.</li><li>• يسمح بالوصول وباحتفاظ بهذه الوثيقة مع مصدرها أو مع المسؤول عن تطبيقها أو مع المطبق عليهم.</li><li>• تصنيف امن المعلومات: <input checked="" type="checkbox"/> بيانات مفتوحة <input type="checkbox"/> مشارك -خاص <input type="checkbox"/> مشارك -حساس <input type="checkbox"/> مشارك -سري</li></ul>
--	--

# DHA TELEHEALTH CLINICAL GUIDELINES FOR LABORATORY MONITORING OF VARIOUS CHRONIC CONDITIONS/ DISEASES - 21

**Issue date:** 27/07/2021

**Effective date:** 27/07/2021

Health Policies and Standards Department

Health Regulation Sector (2021)

## INTRODUCTION

Dubai Health Authority (DHA) is the responsible entity for regulating, licensing and monitoring health facilities and healthcare professionals in the Emirate of Dubai. The Health Regulation Sector (HRS) is an integral part of DHA and was founded to fulfil the following overarching strategic objectives:

Objective #1: Regulate the Health Sector and assure appropriate controls are in place for safe, effective and high-quality care.

Objective #2: Position Dubai as a global medical destination by introducing a value-based, comprehensive, integrated and high-quality service delivery system.

Objective #3: Direct resources to ensure happy, healthy and safe environment for Dubai population.

## ACKNOWLEDGMENT

This document was developed for the Laboratory Monitoring of Various Chronic Conditions/Diseases in collaboration with Subject Matter Experts. The Health Policy and Standards Department would like to acknowledge and thank these professionals for their dedication toward improving the quality and safety of healthcare services.

### The Health Regulation Sector

### Dubai Health Authority

## TABLE OF CONTENTS

<b>EXECUTIVE SUMMARY</b>	<b>4</b>
<b>DEFINITIONS/ABBREVIATIONS</b>	<b>5</b>
<b>1. BACKGROUND</b>	<b>7</b>
<b>2. SCOPE</b>	<b>7</b>
<b>3. PURPOSE</b>	<b>7</b>
<b>4. APPLICABILITY</b>	<b>8</b>
<b>5. RECOMMENDATION</b>	<b>8</b>
<b>REFERENCES</b>	<b>11</b>
<b>APPENDICES</b>	<b>13</b>

## EXECUTIVE SUMMARY

Telehealth is based on Evidence Based Practice (EBP) which is the conscientious, explicit and judicious use of current best evidence in making decisions about the care of the individual patient.

It means integrating individual clinical expertise with the best available external clinical evidence and guidelines from systematic research.

EBP is important because it aims to provide the most effective care virtually, with the aim of improving patient outcomes. As health professionals, part of providing a professional service is ensuring that practice is informed by the best available evidence.

Monitoring of chronic conditions accounts for a significant proportion of blood testing in DHA primary care; not all of this is based on evidence or guidelines. This guideline attempts to set out to standardize the blood tests used for monitoring of some chronic conditions, and to reduce the harms of unwarranted testing.

## DEFINITIONS/ABBREVIATIONS

**Virtual Clinical Assessment:** Is the evaluation of the patient's medical condition virtually via telephone or video call consultations, which may include one or more of the following: patient medical history, physical examination and diagnostic investigations.

**Patient:** The person who receives the healthcare services or the medical investigation or treatment provided by a DHA licensed healthcare professional.

## ABBREVIATIONS

<b>ACE</b>	:	Angiotensin-Converting Enzyme
<b>ACR</b>	:	Albumin Creatinine Ratio
<b>AF</b>	:	Atrial fibrillation
<b>ARB</b>	:	Angiotensin-II Receptor Blocker
<b>CHD</b>	:	Coronary Heart Disease
<b>CKD</b>	:	Chronic Kidney Disease
<b>CVA</b>	:	Cerebrovascular Accident
<b>CVD</b>	:	Cardiovascular Disease
<b>DHA</b>	:	Dubai Health Authority
<b>DM</b>	:	Diabetes Mellitus
<b>EBP</b>	:	Evidence Based Practice
<b>ER</b>	:	Emergency Room

---

<b>FBC</b>	:	Full Blood Count
<b>GORD</b>	:	Gastro-Oesophageal Reflux Disease
<b>HbA1c</b>	:	Haemoglobin A1c
<b>HDL</b>	:	High-Density Lipoprotein
<b>HT</b>	:	Hypertension
<b>IBD</b>	:	Inflammatory Bowel Disease
<b>IHD</b>	:	Ischaemic Heart Disease
<b>IFG</b>	:	Impaired Fasting Glucose
<b>IGT</b>	:	Impaired Glucose Tolerance
<b>KPI</b>	:	Key Performance Indicator
<b>LDL</b>	:	Low-Density Lipoprotein
<b>LFT</b>	:	Liver Function Test
<b>NICE</b>	:	National Institute for Health and Care Excellence
<b>PVD</b>	:	Peripheral Vascular Disease
<b>TIA</b>	:	Transient Ischemic Attack
<b>U&amp;Es</b>	:	Urea and Electrolytes

## 1. BACKGROUND

- 1.1. This guideline outlines the type of laboratory tests that need to be done for some chronic conditions before doctors prescribe and/or adjust the dosages of patients' chronic medications.
- 1.2. It should be noted that Chronic/Repeat Medications only to be prescribed after a video-consultation with a patient. Doctors must ascertain that the precise list of patients' medications, including dosage, frequency and duration are known before issuing the prescription. Patients' medical reports and/or evidence of prescription should always be sought out by doctors.
- 1.3. Doctors must also consider if further blood tests or other investigations need to be done before prescribing the same medication or adjusting the dosages. If doctors have any doubt about patient's exact medication or dosage, then patient should be referred to his/her usual doctor.

## 2. SCOPE

- 2.1. Telehealth services in DHA licensed Health Facilities.

## 3. PURPOSE

- 3.1. To support the implementation of laboratory monitoring of various chronic conditions/diseases.

#### 4. APPLICABILITY

- 4.1. DHA licensed physicians and health facilities providing Telehealth services.
- 4.2. Exclusion for Telehealth services are as follows
  - 4.2.1. Emergency cases where immediate intervention or referral is required.
  - 4.2.2. Prescribe Narcotics, Controlled or Semi-Controlled medications.

#### 5. RECOMMENDATION

- 5.1. Chronic conditions that could be managed virtually

Some of the chronic diseases/ conditions that could be managed virtually include  
(but are not limited to) the following:

- 5.1.1. Hypertensions
- 5.1.2. Hypothyroidism
- 5.1.3. Hyperthyroidism
- 5.1.4. Type 2 Diabetes
- 5.1.5. IGR/IFG/Gestational DM
- 5.1.6. Hypercholesterolemia/hyperlipidaemia
- 5.1.7. Ischaemic Heart Disease
- 5.1.8. Heart Failure
- 5.1.9. AF
- 5.1.10. Asthma
- 5.1.11. COPD



- 5.1.12. Irritable Bowel Syndrome
- 5.1.13. Chronic Constipation
- 5.1.14. Dyspepsia (Gastritis/duodenitis)/GORD
- 5.1.15. IBD (Ulcerative Colitis or Chon's Disease)
- 5.1.16. Chronic back pain
- 5.1.17. Vitamin D deficiency
- 5.1.18. Osteoporosis
- 5.1.19. Peripheral Vascular Disease (PVD)
- 5.1.20. Chronic Kidney Disease (CKD)
- 5.1.21. Old Stroke
- 5.1.22. Other conditions to be managed and repeat medications to be prescribed on doctor's discretion on case-by-case (note: doctors to request lab tests if indicated/as deemed necessary)

## 5.2. Laboratory monitoring of Chronic Conditions

Chronic diseases would require regular monitoring in most cases. The monitoring decision and the type of lab tests required would depend on the following six phases:

- 5.2.1. Pre-treatment monitoring/lab test to determine if a disease or a stage of disease is present
- 5.2.2. After the initiation of treatment.
- 5.2.3. After the disease is treated and stable

- 
- 5.2.4. After a significant change in the disease process or treatment has occurred; or
- 5.2.5. To determine if it is possible to stop treatment
- 5.2.6. Based on doctor's clinical judgment
- 5.3. Refer to APPENDIX 1 for Required Laboratory Tests.
- 5.4. Refer to APPENDIX 2 for Drugs Monitoring and Tests to be done before issuing Repeat Prescriptions.

## REFERENCES

1. NHS Choices (2019). *Health A-Z*. [online] NHS. Available at: <https://www.nhs.uk/conditions/>. [Accessed 10 May 2019].
2. National Institute for Health and Care Excellence (NICE) (2014). *Chronic kidney disease in adults: assessment and management*. [online] Nice.org.uk. Available at: <https://www.nice.org.uk/guidance/cg182/> [Accessed 11 May. 2018].
3. National Institute for Health and Care Excellence (NICE) (2015). *Type 2 diabetes in adults: management*. [online] Nice.org.uk. Available at: <https://www.nice.org.uk/guidance/ng28> [Accessed 11 May 2018].
4. National Institute for Health and Care Excellence (NICE). (2011). *Hypertension in adults: diagnosis and management*. [online] Nice.org.uk. Available at: <https://www.nice.org.uk/guidance/cg127> [Accessed 18 Mar. 2018].
5. National Institute for Health and Care Excellence (NICE) (2011). *Hypertension in adults: diagnosis and management*. [online] Nice.org.uk. Available at: <https://www.nice.org.uk/guidance/cg127> [Accessed 26 Mar. 2018].
6. National Institute for Health and Care Excellence (NICE) (2014). *Cardiovascular disease: risk assessment and reduction, including lipid modification*. [online] Nice.org.uk. Available at: <https://www.nice.org.uk/guidance/cg181/chapter/1-Recommendations> [Accessed 20 May 2018].

7. National Institute for Health and Care Excellence (NICE) (2018). *Overview / Rheumatoid arthritis in adults: management / Guidance / NICE*. [online] Nice.org.uk. Available at: <https://www.nice.org.uk/guidance/ng100> [Accessed 11 May 2018].
8. National Institute for Health and Care Excellence (NICE) (2014). *Atrial fibrillation: management*. [online] Nice.org.uk. Available at: <https://www.nice.org.uk/guidance/CG180> [Accessed 11 May 2018].
9. Ross, D. (2019). *Laboratory assessment of thyroid function*. [online] Uptodate.com. Available at: [https://www.uptodate.com/contents/laboratory-assessment-of-thyroid-function?search=thyroid%20function%20tests%20adult&source=search\\_result&selectedTitle=1~150&usage\\_type=default&display\\_rank=1](https://www.uptodate.com/contents/laboratory-assessment-of-thyroid-function?search=thyroid%20function%20tests%20adult&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1) [Accessed 6 May 2018].

## APPENDICES

### APPENDIX 1 – REQUIRED LABORATORY TESTS: TYPES AND FREQUENCY OF BLOOD TESTS THAT NEED TO BE DONE BEFORE PRESCRIBING MEDICATION FOR CHRONIC DISEASES

Chronic Condition	Baseline Blood tests to be done (or at the time of first diagnosis)	3 Monthly Review	6 Monthly and Annually Review
Hypertension	FBS, Total Cholesterol / HDL. U/E*, urine ACR.	N/A (Provided the baseline lab results were normal)	U/E (only if on ACEi, ARB or Thiazide)
CVA, CHD, PVD	FBS, Total Cholesterol / HDL. U/E*, If urine dip pos protein then send for ACR.	N/A (Provided the baseline lab results were satisfactory/normal)	CBC, cholesterol U/E,
CKD3a (eGFR 45-59)	FBS, Total Cholesterol / HDL, ACR	U/E*, Urine ACR til stable	U/E*, ACR
CKD3b (eGFR 30-44)	FBS, Total Cholesterol / HDL, ACR	U/E, Urine ACR til stable	U/E*, ACR, CBC
CKD4 (eGFR 15-29)	FBS, Total Cholesterol / HDL, ACR, Calcium, Phosphate, PTH	U/E *, Urine ACR	U/E*, ACR, CBC
Diabetes	HbA1C, U/E*, Fasting lipids, ALT, Urine ACR.	HbA1C, Urine ACR,	HbA1C, U/E*, Cholesterol, Urine ACR
IFG, IGT, Gestational Diabetes	HbA1C, U/E*, Fasting glucose and total cholesterol. If urine dip pos protein, then send for ACR	N/A (Provided the baseline lab results were satisfactory/normal)	HbA1C, U/E, Fasting glucose and total cholesterol. Urine ACR,
Gastritis /GORD/	Consider testing for H. pylori if patient has not had this test done despite having a history of chronic gastritis. Also consider checking CBC to check		

	for Hb (to rule out anaemia) if patient had a chronic history of gastritis /GORD.
--	---

Note: If baseline results are unknown (e.g. if patient's previous lab reports are unavailable and chronic medications need to be prescribed) then new lab tests need to be ordered before prescribing chronic medications. Consider repeating U/E within 2 weeks if starting patient on or increasing dosage of ACEi/ARB/Diuretics.

## APPENDIX 2 – DRUGS MONITORING AND TESTS TO BE DONE BEFORE ISSUING REPEAT PRESCRIPTIONS

Name of Drug	Type of tests to be done + Frequency
Statin (e.g. Atorvastatin,	ALT at 3 month and then 12 month and then no more monitoring is needed, and the same medication can be prescribed provided that the ALT is the same. However, ensure that the latest/last cholesterol/lipid level was normal before continuing the same dose. If cholesterol level was high, then the statin dose should be increased and lipid/cholesterol level should have repeated in 3 months' time.
Methotrexate	Refills based on established diagnosis of disease by specialist only. Mandatory tests required are: LFT, U&E, ESR, CBC EVERY 2 WEEKS FOR 6 WEEKS THEN MONTHLY FOR A YEAR AND THEN EVERY 2-3MONTHLY
Sulfasalazine	Refills based on established diagnosis of disease by specialist only. Mandatory tests required are: LFT, ESR, CBC – Monthly for 3months for first year. Then 6monthly for 2 yearly. Can stop monitoring if stable at 2 years.
Azathioprine	Refills based on established diagnosis of disease by specialist only. Mandatory tests required are: LFT, ESR, CBC – Weekly for 6 weeks then monthly. After 6month if stable to these tests 3 monthly
Lithium (only through face to face consultation)	Refills based on established diagnosis of disease by specialist only. 3 monthly lithium levels. Instruct the lab technician / nurse (who takes the blood sample) to mark the form with time of sample and time of last dose. Also do U&E and TFT 6monthly
Amiodarone	6 monthly TFT AND LFT

Antithyroid Drug Therapy (for treatment of Thyrotoxicosis). Antithyroid drugs include: Carbimazole and propylthiouracil	It is recommended that thyroid function (TSH, Free T4, T3) is tested every 1-3 months after initiation of antithyroid drug therapy until stable and annually if used as a long-term treatment option
Thyroxine Therapy (e.g. for patients who are known to have hypothyroidism and are taking levothyroxine)	Check TFTs (TSH, T4 + T3) every 4-6 weekly until levels are stable (normal) and then check TFT at least annually once stable (but test can be done sooner if patient is not compliant or has symptoms of hypothyroidism or on discretion of the prescribing doctor).